Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEL-101 vs Tacrolimus in Kidney Transplant Recipients
NCT07290777Phase 2Recruiting
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of FR104 in kidney transplant rejection, sponsored by Veloxis Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
FR104
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT07290777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290777.